Generic Medicine Info
Indications and Dosage
Adult: For primary cases: 500 mg tid for 10 days, starting 5 days before the onset of menstruation. Alternatively, 500 mg 4 times daily during menses. For intrauterine-device (IUD)-induced cases: 500 mg tid for 10 days, starting 5 days before the onset of menstruation.

Diffuse perioperative haemorrhage
Adult: Prophylaxis and treatment: Preoperative: 500 mg given 1 hour prior to surgery. Postoperative: 500 mg 4-6 hourly as long as bleeding risk persists.

Diffuse perioperative haemorrhage
Adult: Prophylaxis and treatment: Preoperative: 250-500 mg given 1 hour prior to surgery, additional doses may be necessary during operation. Postoperative: 250 mg bid. Alternatively, up to 250-500 mg 4-6 hourly may be given as long as bleeding risk persists. Doses are given via IV or IM.

Acute capillary haemorrhage
Adult: Prophylaxis and treatment: 500-750 mg tid via IV or IM.
May be taken with or without food. May be taken w/ meals to minimise GI upset.
Hypersensitivity to etamsylate. Known hypersensitivity to sulfites, bronchial asthma; acute porphyria. Lactation.
Special Precautions
Patient with hypotension or unstable blood pressure. Pregnancy.
Adverse Reactions
Significant: Hypotension (parenteral). Rarely, severe hypersensitivity reaction, including anaphylaxis.
Blood and lymphatic system disorders: Parenteral: Rarely, neutropenia, agranulocytosis, thrombocytopenia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain or discomfort.
General disorders and administration site conditions: Asthenia (parenteral). Rarely, fever.
Musculoskeletal and connective tissue disorders: Rarely, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Rarely, thromboembolism (parenteral).
Description: Etamsylate is an antihaemorrhagic and vasoprotective agent. It increases platelet adhesiveness and capillary vascular wall resistance, thereby reducing capillary exudation and blood loss.
Synonym: ethamsylate.
Absorption: Slowly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 4-5 hours.
Distribution: Crosses the placenta and enters breast milk. Volume of distribution: 86.6 L. Plasma protein binding: Approx 90-95%.
Excretion: Via urine (approx 72% as unchanged drug). Elimination half-life: Approx 3.7-9.4 hours (oral); 2 hours (IV).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 17506, Etamsylate. Accessed Apr. 27, 2021.

Tab: Store between 15-25°C. Parenteral: Store below 30°C. Protect from light.
MIMS Class
ATC Classification
B02BX01 - etamsylate ; Belongs to the class of other systemic hemostatics. Used in the treatment of hemorrhage.
Anon. Etamsylate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 02/03/2021.

Buckingham R (ed). Etamsylate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 02/03/2021.

Disclaimer: This information is independently developed by MIMS based on Etamsylate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in